Abstract
Results are reported from a randomized, double-blind, trazodone- and placebo-controlled, 6 weeks' efficacy and safety study of a new antidepressant Org 3770 (Remeron®), in 150 outpatients over 55 years of age, with a DSM III diagnosis of moderate to severe major depressive disorder. On the 21-item HAMD, the differences between Org 3770 and placebo were statistically significant at weeks 2, 3, 4 and 6 in both Observed Case and Last Observation Carried Forward analyses. Statistically significant differences between both active compounds and placebo were registered at weeks 2 and 3 on the MADRS. The treatments with both Org 3770 and trazodone were associated with a significantly higher frequency of somnolence and dry mouth as compared to placebo, whereas treatment with trazodone also resulted in significantly higher frequencies of dizziness and blurred vision as compared to placebo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
